American Heart Journal
Volume 158, Issue 2 , Pages 177-184 , August 2009

Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: Results of the STACK-on to ENOXaparin (STACKENOX) study

  • Ludovic Drouet, MD, PhD

      Affiliations

    • Department of Angio-Hematology, Hôpital Lariboisière, AP-HP Paris, France
    • University of Paris VII-Denis Diderot, Paris, France
    • Corresponding Author InformationReprint requests: Ludovic Drouet, MD, PhD, Angio-Hematology Department, Hôpital Lariboisière, 2 rue Ambroise Paré, 75475 Paris cedex 10, Paris, France.
    • ,
  • Claire Bal dit Sollier, MB

      Affiliations

    • Experimental Thrombosis and Atherosclerosis Laboratory, Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris, France
    • ,
  • Jack Martin, MD

      Affiliations

    • Sharpe-Strumia Research Foundation of the Bryn Mawr Hospital, Bryn Mawr, PA

Received 29 January 2009 ,Accepted 18 May 2009.

References 

  1. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447–452
  2. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non–Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602–1608
  3. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non–Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593–1601
  4. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J. 2007;28:2077–2086
  5. Cohen M, Diez JE, Levine GN, et al. Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report-III. J Invasive Cardiol. 2007;12:525–538
  6. Stommel M, Olomu A, Holmes-Rovner M, et al. Changes in practice patterns affecting in-hospital and post-discharge survival among ACS patients. BMC Health Serv Res. 2006;6:140
  7. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non–ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598–1660
  8. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117:296–329
  9. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45–54
  10. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators . Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–1476
  11. Hulot JS, Montalescot G, Lechat P, et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non–ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther. 2005;77:542–552
  12. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1994;23:1061–1065
  13. Al Dieri R, Alban S, Béguin S, et al. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost. 2004;2:1395–1401
  14. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004;110:392–398
  15. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 2001;103:658–663
  16. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol. 2001;13:272–278
  17. Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol. 2002;40:1943–1950
  18. Bijsterveld NR, Moons AH, Meijers JC, et al. The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimenof low-molecular-weight heparin in the initial treatment of acutecoronary syndromes. J Am Coll Cardiol. 2003;42:424–427
  19. Sanchez-Pena P, Hulot JS, Urien S, et al. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol. 2005;60:364–373
  20. Gibson CM, Murphy SA, Montalescot G, et al. Percutaneouscoronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2007;49:2238–2246
  21. Brodin E, Seljeflot I, Arnesen H, et al. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Thromb Res. 2009;123:573–579
  22. Hemker HC, Al Dieri R, De Smedt E, et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553–561
  23. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4–15
  24. Montalescot G, Cohen M, Salette G, et al. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneouscoronary intervention: insights from the STEEPLE trial. Eur Heart J. 2008;29:462–471
  25. Levine GN, Ferrando T. Degree of anticoagulation after onesubcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromesundergoing early percutaneous coronary intervention. J Thromb Thrombolysis. 2004;17:167–171
  26. Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulationwith enoxaparin in patients undergoing percutaneous coronaryintervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv. 2004;61:163–170
  27. King SB, Smith SC, Hirshfeld JW, et al. 2007 Focused Updateof the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College ofCardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117:261–295
  28. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. J Invasive Cardiol. 2000;12(Suppl E):E14–E18[discussion E25-8]
  29. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994;108:1076–1082
  30. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators . Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol. 1997;29:1474–1482
  31. Popma JJ, Weitz J, Bittl JA, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest. 1998;114:728S–741S
  32. Cheneau E, Canos D, Kuchulakanti PK, et al. Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention. Am J Cardiol. 2004;94:789–792
  33. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006;355:1006–1017
  34. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477–1488
  35. White HD, Kleiman NS, Mahaffey KW, et al. Efficacy andsafety of enoxaparin compared with unfractionated heparin inhigh-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary interventionin the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006;152:1042–1050

 Randomized clinical trial no.: NCT00622115.

 Prof Drouet reports receiving grant support from sanofi-aventis, Eli Lilly, and GSK, and consulting and lecture fees from sanofi-aventis, BMS, AstraZeneca, The Medicine Company, GSK, Servier, Cordis and Boehringer-Ingelheim. Dr Bal dit Sollier reports being an employee of the Blood and Vessel Institute and receiving grant support from sanofi-aventis and Eli Lilly. Dr Martin reports receiving consulting and lecture fees from sanofi-aventis.

PII: S0002-8703(09)00386-X

doi: 10.1016/j.ahj.2009.05.022

American Heart Journal
Volume 158, Issue 2 , Pages 177-184 , August 2009

Article Tools

* Image Usage & Resolution